These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 9888019)

  • 1. Phase III, large-scale chemoprevention trials. Approach to chemoprevention clinical trials and phase III clinical trial of tamoxifen as a chemopreventive for breast cancer--the US National Cancer Institute experience.
    Dunn BK; Kramer BS; Ford LG
    Hematol Oncol Clin North Am; 1998 Oct; 12(5):1019-36, vii. PubMed ID: 9888019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
    Greenwald P
    J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results and implications of the Royal Marsden and other tamoxifen chemoprevention trials.
    Ross PJ; Powles TJ
    Clin Breast Cancer; 2001 Apr; 2(1):33-6; discussion 37-40. PubMed ID: 11899380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoprevention of breast cancer.
    Dalton RR; Kallab AM
    South Med J; 2001 Jan; 94(1):7-15. PubMed ID: 11213947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoprevention of breast cancer.
    Osborne MP
    Surg Clin North Am; 1999 Oct; 79(5):1207-21. PubMed ID: 10572559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trials.
    Unger JM; Barlow WE; Tangen CM; Ramsey SD; Thompson IM; Klein EA; LeBlanc M; Blanke CD; Goodman PJ; Minasian LM; Nghiem VT; Hershman DL
    Cancer Epidemiol; 2018 Aug; 55():117-122. PubMed ID: 29936140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chemoprevention of breast cancer: a hope justified?].
    Buser K; Delaloye JF
    Rev Med Suisse Romande; 2000 Jun; 120(6):511-3. PubMed ID: 11014095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of breast cancer chemopreventive drugs.
    Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Doody LA; Greenwald P
    J Cell Biochem Suppl; 1993; 17G():2-13. PubMed ID: 8007699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tamoxifen and breast cancer--from palliation to prevention.
    Rich SE
    Cancer Nurs; 1993 Oct; 16(5):341-6. PubMed ID: 7505194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent results from clinical trials using SERMs to reduce the risk of breast cancer.
    Vogel VG
    Ann N Y Acad Sci; 2006 Nov; 1089():127-42. PubMed ID: 17261762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on breast cancer prevention.
    Rastogi P; Vogel VG
    Oncology (Williston Park); 2003 Jun; 17(6):799-805; discussion 808-10, 813. PubMed ID: 12846124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer prevention with selective estrogen receptor modulators: a perspective.
    Pritchard KI
    Ann N Y Acad Sci; 2001 Dec; 949():89-98. PubMed ID: 11795385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts.
    Vogel VG
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4413s-4418s; discussion 4411s-4412s. PubMed ID: 11916233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoprevention: drug pricing and mortality: the case of tamoxifen.
    Melnikow J; Kuenneth C; Helms LJ; Barnato A; Kuppermann M; Birch S; Nuovo J
    Cancer; 2006 Sep; 107(5):950-8. PubMed ID: 16865680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk biomarkers and current strategies for cancer chemoprevention.
    Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
    J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Royal Marsden Hospital (RMH) trial: key points and remaining questions.
    Powles TJ
    Ann N Y Acad Sci; 2001 Dec; 949():109-12. PubMed ID: 11795342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An overview of clinical cancer chemoprevention studies with emphasis on positive phase III studies.
    Alberts DS; Garcia DJ
    J Nutr; 1995 Mar; 125(3 Suppl):692S-697S. PubMed ID: 7884553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress in chemoprevention of breast cancer.
    Serrano D; Perego E; Costa A; Decensi A
    Crit Rev Oncol Hematol; 2004 Feb; 49(2):109-17. PubMed ID: 15012972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.